Noopept (powder) – 10g

Noopept (omberacetam, GVS-111) is a synthetic dipeptide designed as an analog of the nootropic piracetam, studied for memory and protection of nerve cells.

• Mild cognitive impairment after stroke or brain injury (small studies)
• NGF and BDNF expression in the rat hippocampus
• Oxidative damage in human neuron cultures

In rats it raised hippocampal expression of NGF and BDNF, two growth factors for neurons. In human neuron cultures it acted as an antioxidant and reduced cell death.

1. Human · small / uncontrolled

   Cognitive impairment after stroke (2011)

   Open study of 60 people with mild cognitive impairment after stroke; cognitive test scores improved significantly after 2 months compared with the control group.[1]

2. Human · small / uncontrolled

   EEG study (2008)

   In patients with mild cognitive impairment after brain injury or vascular disease, it increased alpha and beta EEG power and reduced delta power - a pattern the authors describe as typical of nootropics.[2]

3. Animal study

   NGF and BDNF in rats (Bull Exp Biol Med 2008)

   Single and 28-day treatment raised NGF and BDNF messenger RNA in the rat hippocampus, with no tolerance on repeated treatment.[3]

4. Cells / in vitro

   Human neuron cultures (Int J Dev Neurosci 2003)

   Protected human cortical neurons, including Down's syndrome neurons, from oxidative damage and cell death - more than piracetam or vitamin E did in the same model.[4]

5. Product testing

   U.S. supplement testing (Neurol Clin Pract 2021)

   Detected as omberacetam in U.S. cognitive supplements; the authors describe it as not approved for human use in the United States and found labels that often misstated the contents.[5]

• The human studies are small and open-label; no randomized, placebo-controlled trial was identified.
• Products on this site are sold for laboratory research only. They are not the medicines used in the trials above, and those results do not apply to research material.

1. 1.Noopept in the treatment of mild cognitive impairment in patients with strokeAmelin AV et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2011 Human · small / uncontrolled
2. 2.Clinical and electroencephalographic characteristic of noopept in patients with mild cognitive impairment of posttraumatic and vascular originBochkarev VK et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2008 Human · small / uncontrolled
3. 3.Noopept stimulates the expression of NGF and BDNF in rat hippocampusOstrovskaya RU et al. Bull Exp Biol Med. 2008 Animal study
4. 4.GVS-111 prevents oxidative damage and apoptosis in normal and Down's syndrome human cortical neuronsPelsman A et al. Int J Dev Neurosci. 2003 Cells / in vitro
5. 5.Five Unapproved Drugs Found in Cognitive Enhancement SupplementsCohen PA et al. Neurol Clin Pract. 2021 Product testing